{"product_id":"postmenopausal-osteoporosis-a-complete-patient-guide","title":"Postmenopausal Osteoporosis: A Complete Patient Guide","description":"\u003cp\u003ePostmenopausal osteoporosis is a common condition caused by estrogen deficiency after menopause, leading to fragile bones and an increased risk of fractures. About half of all postmenopausal women will experience a fragility fracture (a fracture from minimal trauma), and the costs in the United States already exceed $57 billion per year. This patient-focused article explains how osteoporosis is diagnosed and evaluated, reviews the lifestyle changes and medications that can prevent fractures, and clarifies how doctors decide who needs treatment—especially women at “very high risk.” It is based on a comprehensive clinical practice review published in the \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e.\u003c\/p\u003e\n\n\u003ch1\u003ePostmenopausal Osteoporosis: A Complete Patient Guide\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eUnderstanding Postmenopausal Osteoporosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eHow Osteoporosis Is Diagnosed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risk-factors\"\u003eRisk Factors and Causes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#evaluation\"\u003eEvaluation and Testing\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-lifestyle\"\u003eTreatment: Goals and Lifestyle Changes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#medications\"\u003eMedication Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#choosing-treatment\"\u003eChoosing the Right Treatment: High vs. Very High Risk\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-points\"\u003eKey Clinical Points You Should Know\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of Current Knowledge\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eWhat Should You Do? (Recommendations for Patients)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePostmenopausal osteoporosis is common and can cause fragility fractures, leading to pain, disability, and high health care costs.\u003c\/li\u003e\n\u003cli\u003eDXA bone density testing is recommended for women 65 or older, and for younger postmenopausal women with risk factors.\u003c\/li\u003e\n\u003cli\u003eOsteoporosis is diagnosed by a fragility fracture or a T score of -2.5 or lower on DXA.\u003c\/li\u003e\n\u003cli\u003eAnabolic agents are preferred initial treatment for women at very high fracture risk.\u003c\/li\u003e\n\u003cli\u003eStopping denosumab without transitioning to another treatment can cause rebound bone loss and fractures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eUnderstanding Postmenopausal Osteoporosis\u003c\/h2\u003e\n\n\u003cp\u003eThe clinical problem starts with a common scenario: a 69-year-old woman has just received her first bone density scan (called dual-energy x-ray absorptiometry, or DXA). Her T scores are −2.6 at the lumbar spine and −2.3 at the total hip. She fell while walking 18 months ago and fractured her left humerus (upper arm bone). Imaging of her spine, performed because she lost 5 cm (2 inches) of height and developed moderate thoracic kyphosis (a forward curvature of the upper back), shows two vertebral compression fractures. How should this patient be evaluated and treated?\u003c\/p\u003e\n\n\u003cp\u003ePostmenopausal osteoporosis is caused by estrogen deficiency after menopause. Low estrogen levels increase the activity of osteoclasts (cells that break down bone) and speed up bone resorption—the process of removing bone tissue—so that bone loss outpaces bone formation. This is especially rapid in the years immediately before and after menopause. The result is low bone mineral density, deteriorated bone microarchitecture, decreased bone strength, and a higher risk of fragility fractures.\u003c\/p\u003e\n\n\u003cp\u003eFragility fractures are defined as those occurring with no associated trauma, or with trauma equivalent to falling from a standing height or less. These fractures are extremely common and cause pain, disability, and reduced quality of life. After a hip fracture, many women never regain independence. In fact, 20% are institutionalized, and the risk of death within 1 year doubles. Non-White women who have hip fractures are more likely to die within 6 months, less likely to regain independence, and receive less timely surgery and rehabilitation than White women. The annual health care cost associated with postmenopausal osteoporosis fractures in the United States is currently \u003cstrong\u003e$57 billion\u003c\/strong\u003e, and this is projected to exceed \u003cstrong\u003e$95 billion by 2040\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eHow Osteoporosis Is Diagnosed\u003c\/h2\u003e\n\n\u003cp\u003eOsteoporosis is asymptomatic until the first clinical fracture. The gold standard for identifying patients at risk is bone mineral density measurement with DXA. Each standard deviation (SD) reduction below a T score of 0 is associated with \u003cstrong\u003ea doubling or tripling in the risk of fracture\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eMost guidelines recommend DXA of the spine and hip for postmenopausal women 65 years of age or older, and for postmenopausal women younger than 65 who have risk factors. Forearm bone mineral density can also predict fracture, and may be measured when the recommended sites are not evaluable, or when hyperparathyroidism is present.\u003c\/p\u003e\n\n\u003cp\u003eOsteoporosis is formally diagnosed when either of the following is present:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA fragility fracture (especially of the spine, hip, wrist, humerus, or pelvis), even if the T score is above −2.5\u003c\/li\u003e\n  \u003cli\u003eA bone mineral density T score of \u003cstrong\u003e−2.5 or lower\u003c\/strong\u003e at the lumbar spine, total hip, or femoral neck (the top of the thigh bone)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn the United States, approximately \u003cstrong\u003e20% of women over 50\u003c\/strong\u003e and \u003cstrong\u003e30% of women 65 or older\u003c\/strong\u003e meet DXA criteria for osteoporosis. Osteoporosis is more common among White, Asian, and Hispanic women than among non-Hispanic Black women. An additional \u003cstrong\u003e40% of postmenopausal women\u003c\/strong\u003e have low bone mass (osteopenia, defined as a T score between −1.0 and −2.49).\u003c\/p\u003e\n\n\u003cp\u003eFragility fractures of the spine, hip, forearm, humerus, and pelvis are diagnostic of osteoporosis even when T scores are higher than −2.5. The occurrence of a fragility fracture is associated with a marked increase in the \u003cstrong\u003eimminent risk\u003c\/strong\u003e of additional fractures. Vertebral compression fractures are the most common osteoporotic fractures; they are frequently painful and cause height loss, but they may be asymptomatic. Vertebral fractures are associated with increased mortality, and their presence influences diagnosis, risk stratification, and treatment decisions.\u003c\/p\u003e\n\n\u003ch2 id=\"risk-factors\"\u003eRisk Factors and Causes\u003c\/h2\u003e\n\n\u003cp\u003eSeveral clinical risk factors increase a woman’s chance of having osteoporosis or a fracture. According to the article, the key risk factors include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOlder age\u003c\/li\u003e\n  \u003cli\u003eLow body weight (less than 127 pounds or 58 kg)\u003c\/li\u003e\n  \u003cli\u003ePrevious fracture during adulthood (particularly hip, spine, or wrist); a recent fracture indicates a higher risk than a remote or unclear history\u003c\/li\u003e\n  \u003cli\u003eParental history of hip fracture\u003c\/li\u003e\n  \u003cli\u003eCurrent or past glucocorticoid treatment (more than 5 mg of prednisolone daily, or the equivalent, for 3 months or more)\u003c\/li\u003e\n  \u003cli\u003eUse of other medications that cause bone loss, including aromatase inhibitors, suppressive doses of thyroid hormone, chemotherapy, cyclosporine, unfractionated and low-molecular-weight heparins, antidepressants, thiazolidinediones, selected anticonvulsant drugs, and proton-pump inhibitors\u003c\/li\u003e\n  \u003cli\u003eCurrent smoking\u003c\/li\u003e\n  \u003cli\u003eExcess alcohol intake\u003c\/li\u003e\n  \u003cli\u003eConditions that cause secondary osteoporosis, such as rheumatoid arthritis, premature menopause (before age 40) or hypogonadism, organ transplantation, primary hyperparathyroidism, chronic kidney disease, type 1 and type 2 diabetes, anorexia nervosa, hypopituitarism, malabsorption, bariatric surgery, immobility, untreated hyperthyroidism, chronic pulmonary disease, HIV infection, Cushing’s disease, osteogenesis imperfecta, Gaucher’s disease, and Marfan syndrome\u003c\/li\u003e\n  \u003cli\u003eFrequent falls\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"evaluation\"\u003eEvaluation and Testing\u003c\/h2\u003e\n\n\u003cp\u003eThe evaluation of a woman with suspected or confirmed postmenopausal osteoporosis starts with a thorough history focusing on previous fractures and risk factors. A physical examination should look for kyphosis and height loss. If height loss is greater than 1.5 inches (3.8 cm) or other signs suggest vertebral fracture, the doctor should order spine imaging—either vertebral fracture analysis (a low-radiation image obtained on a densitometer) or standard spine radiography.\u003c\/p\u003e\n\n\u003cp\u003eFracture risk can be estimated using the fracture risk assessment tool (FRAX) or other validated calculators. FRAX estimates the 10-year probability of a major osteoporotic fracture and of a hip fracture, based on clinical risk factors, with or without bone mineral density measurement. Many experts consider a \u003cstrong\u003ehip fracture risk of ≥3%\u003c\/strong\u003e or a \u003cstrong\u003emajor osteoporotic fracture risk of ≥20%\u003c\/strong\u003e to be high enough to treat, even if the T score is above −2.5.\u003c\/p\u003e\n\n\u003cp\u003eAnother tool is the trabecular bone score (TBS), an FDA-cleared, Medicare-covered measure obtained from a DXA image using additional software. TBS is an indirect measurement of spine trabecular microarchitecture (the internal structure of bone), and it predicts fracture risk independent of bone mineral density. It can be used to adjust FRAX scores and is most useful when it influences treatment decisions—for example, in women with osteopenia or when fracture risk is close to an intervention threshold. TBS should not be used alone to diagnose osteoporosis.\u003c\/p\u003e\n\n\u003cp\u003eNewer FDA-approved software also allows “opportunistic screening” from routine clinical CT scans to measure volumetric bone mineral density, bone strength, and prevalent vertebral fractures. Evidence suggests this technology performs at least as well as DXA. High-resolution peripheral quantitative CT (HRpQCT) can also measure bone microstructure and strength and predicts fracture risk independently, but it is not FDA-approved for diagnosis.\u003c\/p\u003e\n\n\u003cp\u003eThe article also emphasizes that laboratory evaluation is necessary. At minimum, doctors should measure serum creatinine, calcium, albumin, 25-hydroxyvitamin D, alkaline phosphatase, phosphate, and a complete blood count (CBC) to exclude contraindications to medications. Other tests may be appropriate depending on the situation, including parathyroid hormone (PTH), serum or urine protein electrophoresis (SPEP\/UPEP), thyroid-stimulating hormone (TSH), erythrocyte sedimentation rate (ESR), celiac disease testing (transglutaminase IgA antibody and IgA level), and 24-hour urine calcium. These tests help identify alternative diagnoses such as osteomalacia, primary hyperparathyroidism, cancer, myeloma, chronic kidney disease–mineral and bone disorder, and other metabolic bone diseases.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment-lifestyle\"\u003eTreatment: Goals and Lifestyle Changes\u003c\/h2\u003e\n\n\u003cp\u003eThe fundamental goal of treatment is to \u003cstrong\u003eprevent fractures\u003c\/strong\u003e—either before the first fracture (primary prevention) or before a subsequent fracture (secondary prevention). Lifestyle modifications apply to all women with postmenopausal osteoporosis. Patients should be encouraged to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eStop smoking\u003c\/li\u003e\n  \u003cli\u003eAvoid excessive alcohol\u003c\/li\u003e\n  \u003cli\u003eIncrease weight-bearing exercise\u003c\/li\u003e\n  \u003cli\u003ePrevent falls\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMost guidelines recommend \u003cstrong\u003e1000 to 1200 mg of calcium daily\u003c\/strong\u003e, preferably from diet, and \u003cstrong\u003e400 to 1000 IU of vitamin D daily\u003c\/strong\u003e. Some experts suggest adjusting vitamin D intake to achieve serum 25-hydroxyvitamin D levels above 20 to 30 ng per milliliter, although this approach is controversial and not supported by rigorous data.\u003c\/p\u003e\n\n\u003cp\u003eThe evidence for calcium and vitamin D supplementation in reducing fractures is debated. Limited evidence suggests that supplemental calcium combined with vitamin D significantly reduces \u003cstrong\u003ehip fractures\u003c\/strong\u003e, but not nonvertebral or vertebral fractures, in patients with postmenopausal osteoporosis. Still, because most osteoporosis medications were studied together with calcium and vitamin D, and some medications can cause low blood calcium (hypocalcemia), adequate intake is prudent. Potential risks of calcium supplements include kidney stones (nephrolithiasis) and, according to some meta-analyses, an increased incidence of cardiovascular events—although the studies in those meta-analyses were not designed to assess cardiovascular outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"medications\"\u003eMedication Options\u003c\/h2\u003e\n\n\u003cp\u003ePharmacologic therapies for postmenopausal osteoporosis work by either \u003cstrong\u003ereducing bone resorption\u003c\/strong\u003e (antiresorptive medications) or \u003cstrong\u003estimulating bone formation\u003c\/strong\u003e (anabolic medications). All approved medications reduce vertebral fracture risk, and some also reduce nonvertebral and hip fracture risk. The choice of therapy must consider osteoporosis severity, fracture risk, coexisting conditions, and patient preferences and contraindications.\u003c\/p\u003e\n\n\u003ch3\u003eBisphosphonates\u003c\/h3\u003e\n\n\u003cp\u003eFor women at high risk of fracture, most guidelines recommend bisphosphonates as initial treatment because of their efficacy, safety, convenience, low cost, and lasting effects after stopping. Four oral and intravenous bisphosphonates are FDA-approved for postmenopausal osteoporosis:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlendronate\u003c\/strong\u003e (10 mg daily or 70 mg weekly orally) – reduces vertebral fractures by \u003cstrong\u003e44%\u003c\/strong\u003e, hip fractures by \u003cstrong\u003e40%\u003c\/strong\u003e, and nonvertebral fractures by \u003cstrong\u003e17%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisedronate\u003c\/strong\u003e (5 mg daily, 35 mg weekly, or 150 mg monthly orally) – reduces vertebral fractures by \u003cstrong\u003e36%\u003c\/strong\u003e, hip by \u003cstrong\u003e26%\u003c\/strong\u003e, and nonvertebral by \u003cstrong\u003e20%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIbandronate\u003c\/strong\u003e (2.5 mg daily or 150 mg monthly orally, or 3 mg every 3 months intravenously) – reduces vertebral fractures by \u003cstrong\u003e31%\u003c\/strong\u003e; evidence does not show a reduction in hip or nonvertebral fractures.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZoledronic acid\u003c\/strong\u003e (5 mg per year intravenously) – reduces vertebral fractures by \u003cstrong\u003e56%\u003c\/strong\u003e, hip by \u003cstrong\u003e42%\u003c\/strong\u003e, and nonvertebral by \u003cstrong\u003e18%\u003c\/strong\u003e. When given within 90 days after hip fracture repair and annually for 3 years, zoledronate also reduced the risk of death, though the mechanism is unclear.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOral bisphosphonates are poorly absorbed and can irritate the upper gastrointestinal tract. Intravenous zoledronate is preferred for patients with gastrointestinal side effects or esophageal dysfunction. Acute-phase reactions (fever, muscle aches) may occur with zoledronate but can be reduced with hydration and acetaminophen before and after the infusion.\u003c\/p\u003e\n\n\u003cp\u003eLong-term bisphosphonate use has been associated with rare complications: \u003cstrong\u003eosteonecrosis of the jaw\u003c\/strong\u003e (an area of exposed bone in the jaw that does not heal within 8 weeks) and \u003cstrong\u003eatypical femur fractures\u003c\/strong\u003e (low-trauma fractures in the thigh bone with specific x-ray patterns). In patients taking standard doses for postmenopausal osteoporosis, these risks are estimated to be \u003cstrong\u003every low\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eDenosumab\u003c\/h3\u003e\n\n\u003cp\u003eDenosumab is a human monoclonal antibody that binds to RANK ligand (RANKL), inhibiting osteoclast formation, function, and survival. It is given as \u003cstrong\u003e60 mg subcutaneously every 6 months\u003c\/strong\u003e. In 3-year randomized controlled trials, denosumab lowered the risk of spine, hip, and nonvertebral fractures compared with placebo, with reductions of \u003cstrong\u003e68%\u003c\/strong\u003e for vertebral, \u003cstrong\u003e40%\u003c\/strong\u003e for hip, and \u003cstrong\u003e20%\u003c\/strong\u003e for nonvertebral fractures. In long-term, open-label extension studies, the lower fracture risk was maintained.\u003c\/p\u003e\n\n\u003cp\u003eAlthough gains in bone mineral density are greater with denosumab than with bisphosphonates, evidence for a greater reduction in fracture risk is limited. Rare side effects include osteonecrosis of the jaw, atypical femur fracture, and hypocalcemia—particularly in patients with advanced chronic kidney disease (stage 4 or 5) or vitamin D deficiency. It is important to note that \u003cstrong\u003estopping denosumab can cause rebound bone loss and an increased risk of fractures\u003c\/strong\u003e, so patients should not discontinue it without discussing a transition to another treatment with their doctor.\u003c\/p\u003e\n\n\u003ch3\u003eEstrogen Therapy (CEE)\u003c\/h3\u003e\n\n\u003cp\u003eConjugated equine estrogen (CEE, 0.625 mg daily orally) decreases bone resorption. In trials, it reduced vertebral fractures by \u003cstrong\u003e34%\u003c\/strong\u003e, hip by \u003cstrong\u003e29%\u003c\/strong\u003e, and nonvertebral by \u003cstrong\u003e21%\u003c\/strong\u003e. However, estrogen therapy carries significant risks: when used alone, it can increase the risk of stroke; when combined with medroxyprogesterone, it increases risks of venous thromboembolism (blood clots), stroke, coronary heart disease, breast cancer, dementia, and thromboembolic events. It is contraindicated in women with a history of breast cancer, coronary heart disease, active liver disease, unexplained vaginal bleeding, or increased risk of endometrial cancer.\u003c\/p\u003e\n\n\u003ch3\u003eSERMs (Selective Estrogen Receptor Modulators)\u003c\/h3\u003e\n\n\u003cp\u003eRaloxifene (60 mg daily orally) is a SERM that has weak estrogen agonist activity in bone and decreases osteoclastic bone resorption. It reduces vertebral fractures by \u003cstrong\u003e40%\u003c\/strong\u003e, but has not been shown to reduce hip or nonvertebral fractures. Side effects include venous thromboembolism (VTE), hot flashes, night sweats, peripheral edema, leg cramps, and an increased risk of death from stroke. It is contraindicated in women with a history of VTE, pulmonary embolism, or retinal vein thrombosis.\u003c\/p\u003e\n\n\u003ch3\u003eAnabolic Agents (PTH Analogues)\u003c\/h3\u003e\n\n\u003cp\u003eAnabolic agents stimulate bone formation and are generally reserved for women at very high risk of fracture. Two FDA-approved medications are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTeriparatide\u003c\/strong\u003e (PTH 1-34), 20 μg daily subcutaneously – reduces vertebral fractures by \u003cstrong\u003e74%\u003c\/strong\u003e and nonvertebral fractures by \u003cstrong\u003e39%\u003c\/strong\u003e; hip fracture reduction was not demonstrated in trials. Common side effects include hypercalcemia, muscle cramps, nausea, headache, dizziness, and hypotension.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbaloparatide\u003c\/strong\u003e (PTH-rP analogue), 80 μg daily subcutaneously – reduces vertebral fractures by \u003cstrong\u003e87%\u003c\/strong\u003e and nonvertebral fractures by \u003cstrong\u003e46%\u003c\/strong\u003e; hip fracture reduction was not demonstrated. Side effects are similar to teriparatide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAnabolic agents are contraindicated in women with bone metastases, skeletal cancers, a history of skeletal radiation, increased risk of osteosarcoma (a rare bone cancer), Paget’s disease, hypercalcemic disorders, unexplained elevated alkaline phosphatase, or hypersensitivity to the medication.\u003c\/p\u003e\n\n\u003ch2 id=\"choosing-treatment\"\u003eChoosing the Right Treatment: High vs. Very High Risk\u003c\/h2\u003e\n\n\u003cp\u003eDoctors categorize patients with osteoporosis into \u003cstrong\u003e“high risk”\u003c\/strong\u003e or \u003cstrong\u003e“very high risk”\u003c\/strong\u003e to guide treatment selection. “High risk” is typically defined as meeting minimal intervention thresholds—for example, a T score of −2.5 or lower, a fragility fracture, or a FRAX 10-year risk of hip fracture ≥3% or major osteoporotic fracture ≥20%. “Very high risk” is typically defined as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA T score of less than \u003cstrong\u003e−3.0\u003c\/strong\u003e, or\u003c\/li\u003e\n  \u003cli\u003eA fragility fracture plus a T score of −2.5 or lower, or\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMultiple vertebral fractures\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause anabolic agents (teriparatide or abaloparatide) stimulate new bone formation and have the greatest fracture-risk-reduction effects, \u003cstrong\u003emost guidelines recommend anabolic agents as the initial treatment for women at very high risk\u003c\/strong\u003e, unless there are contraindications. For women at high risk (but not very high risk), bisphosphonates are typically the first choice. Denosumab is also an antiresorptive option and may be considered in certain circumstances, such as when oral bisphosphonates are not tolerated or in women with chronic kidney disease (after careful evaluation).\u003c\/p\u003e\n\n\u003cp\u003eReturning to the case of the 69-year-old woman in the opening vignette: she has two vertebral fractures, a T score of −2.6 at the spine, and a prior humerus fracture from a fall. She meets the criteria for \u003cstrong\u003every high risk\u003c\/strong\u003e because of multiple vertebral fractures, even though her T score is not below −3.0. According to the authors’ recommendations, this patient should be started on an anabolic agent (teriparatide or abaloparatide) to reduce her imminent risk of subsequent fractures.\u003c\/p\u003e\n\n\u003ch2 id=\"key-points\"\u003eKey Clinical Points You Should Know\u003c\/h2\u003e\n\n\u003cul\u003e\n  \u003cli\u003eFragility fractures are very common among postmenopausal women and are associated with increased illness, death, and health care costs.\u003c\/li\u003e\n  \u003cli\u003eDXA (bone density testing) is recommended in postmenopausal women 65 years of age or older, and in younger postmenopausal women who have risk factors.\u003c\/li\u003e\n  \u003cli\u003eOsteoporosis is diagnosed on the basis of a fragility fracture or a DXA T score of −2.5 or less.\u003c\/li\u003e\n  \u003cli\u003eTreatment is recommended for patients with any of the following:\n    \u003cul\u003e\n      \u003cli\u003eA fragility fracture (or fractures), especially of the hip or spine, regardless of bone mineral density\u003c\/li\u003e\n      \u003cli\u003eA T score of −2.5 or less at the lumbar spine, total hip, or femoral neck\u003c\/li\u003e\n      \u003cli\u003eA high 10-year fracture risk (hip fracture risk ≥3% or major osteoporotic fracture risk ≥20%) according to the FRAX tool\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/li\u003e\n  \u003cli\u003eEvaluation should include risk stratification (based on T score, presence of fractures, and FRAX score) to categorize patients as “high risk” or “very high risk.”\u003c\/li\u003e\n  \u003cli\u003eThe choice of therapy must consider coexisting conditions and contraindications, but \u003cstrong\u003eanabolic agents are the preferred first-line treatment in women at very high risk\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of Current Knowledge\u003c\/h2\u003e\n\n\u003cp\u003eThis clinical practice review acknowledges several areas of uncertainty. First, intervention thresholds vary among different guidelines; for example, some suggest treating women with FRAX-estimated high risk even without a low T score, but the evidence supporting treatment based purely on FRAX is less robust than evidence based on T scores or existing fractures. Second, whether calcium and vitamin D supplementation actually reduces fractures remains debated—limited evidence shows a reduction in hip fractures, but not in nonvertebral or vertebral fractures. Third, some meta-analyses suggest a possible increase in cardiovascular events with calcium supplements, but those studies were not designed to assess cardiovascular outcomes. Fourth, the optimal duration of therapy and the best sequence of treatments (antiresorptive after anabolic, or vice versa) are not fully defined. Finally, although very low, the risks of rare complications such as osteonecrosis of the jaw and atypical femur fractures with long-term antiresorptive use should be shared with patients.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eWhat Should You Do? (Recommendations for Patients)\u003c\/h2\u003e\n\n\u003cp\u003eIf you are a postmenopausal woman, talk to your doctor about your risk factors for osteoporosis and whether you need a DXA scan. The following steps can help protect your bones and prevent fractures:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk factors.\u003c\/strong\u003e If you are 65 or older, or younger than 65 with risk factors, ask for a DXA scan.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet enough calcium and vitamin D.\u003c\/strong\u003e Aim for 1000–1200 mg of calcium daily (preferably from food) and 400–1000 IU of vitamin D daily, as recommended by guidelines. Do not over-supplement without medical advice.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExercise.\u003c\/strong\u003e Weight-bearing exercises (walking, dancing, stair climbing) and strength training can help maintain bone density and reduce fall risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStop smoking and limit alcohol.\u003c\/strong\u003e Both increase bone loss and fracture risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevent falls.\u003c\/strong\u003e Improve home safety, check vision, and discuss any balance issues with your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have already had a fragility fracture, or your T score is −2.5 or lower, ask your doctor about starting medication.\u003c\/strong\u003e If you are at very high risk—for example, multiple vertebral fractures—discuss whether an anabolic agent (teriparatide or abaloparatide) is appropriate for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop osteoporosis medications without talking to your doctor.\u003c\/strong\u003e Some drugs, like denosumab, require a transition to another treatment to prevent rebound bone loss and fractures.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe article emphasizes that osteoporosis is treatable and that effective options exist to significantly reduce fracture risk. No single treatment works for everyone, so the choice of medication should be made together with your doctor, taking into account your fracture risk, other medical conditions, and personal preferences.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is postmenopausal osteoporosis?\u003c\/h3\u003e\n\u003cp\u003ePostmenopausal osteoporosis is a condition caused by estrogen deficiency after menopause. Low estrogen increases bone breakdown, leading to low bone density, weakened bone structure, and higher fracture risk. About half of all postmenopausal women will experience a fragility fracture, which occurs from minimal trauma, such as falling from standing height.\u003c\/p\u003e\n\u003ch3\u003eHow is osteoporosis diagnosed?\u003c\/h3\u003e\n\u003cp\u003eOsteoporosis is diagnosed if you have a fragility fracture, especially of the spine, hip, wrist, humerus, or pelvis, even if your bone density T score is above -2.5. It is also diagnosed if a DXA scan shows a T score of -2.5 or lower at the lumbar spine, total hip, or femoral neck.\u003c\/p\u003e\n\u003ch3\u003eWho should get a bone density test?\u003c\/h3\u003e\n\u003cp\u003eMost guidelines recommend DXA bone density testing for postmenopausal women age 65 or older. Testing is also recommended for younger postmenopausal women who have risk factors, such as previous fracture, parental hip fracture, low body weight, smoking, or use of medications like glucocorticoids.\u003c\/p\u003e\n\u003ch3\u003eWhat lifestyle changes help protect bones?\u003c\/h3\u003e\n\u003cp\u003eLifestyle changes include stopping smoking, limiting alcohol, doing weight-bearing exercise, and preventing falls. Most guidelines recommend 1000 to 1200 mg of calcium daily, preferably from diet, and 400 to 1000 IU of vitamin D daily. Getting enough calcium and vitamin D is especially important when taking osteoporosis medications.\u003c\/p\u003e\n\u003ch3\u003eWhat medications are available for osteoporosis?\u003c\/h3\u003e\n\u003cp\u003eMedication options include bisphosphonates (like alendronate and zoledronic acid), denosumab, estrogen therapy, raloxifene, and anabolic agents (teriparatide and abaloparatide). All approved medications reduce vertebral fracture risk, and some also reduce hip and nonvertebral fracture risk. Your doctor chooses based on your fracture risk and medical conditions.\u003c\/p\u003e\n\u003ch3\u003eWhen are anabolic agents recommended?\u003c\/h3\u003e\n\u003cp\u003eAnabolic agents, such as teriparatide or abaloparatide, are generally recommended as initial treatment for women at very high risk of fracture. Very high risk includes a T score below -3.0, a fragility fracture with a T score of -2.5 or lower, or multiple vertebral fractures. These medications stimulate new bone formation.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in the \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal title:\u003c\/strong\u003e Postmenopausal Osteoporosis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAuthors:\u003c\/strong\u003e Marcella Donovan Walker, M.D., and Elizabeth Shane, M.D.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJournal:\u003c\/strong\u003e N Engl J Med 2023;389:1979-91\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1056\/NEJMcp2307353\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePublication date:\u003c\/strong\u003e November 23, 2023\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCopyright:\u003c\/strong\u003e © 2023 Massachusetts Medical Society\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNote: This article is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider for personal medical decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024735900,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/postmenopausal-osteoporosis-a-complete-patient-guide","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}